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Although the renin-angiotensin system (RAS) was classically considered as a circulating
system that regulates blood pressure, many tissues are now known to have a local RAS.
Angiotensin, via type 1 receptors, is a major activator of the NADPH-oxidase complex,
which mediates several key events in oxidative stress (OS) and inflammatory processes
involved in the pathogenesis of major aging-related diseases. Several studies have
demonstrated the presence of RAS components in the basal ganglia, and particularly in the
nigrostriatal system. In the nigrostriatal system, RAS hyperactivation, via NADPH-oxidase
complex activation, exacerbates OS and the microglial inflammatory response and
contributes to progression of dopaminergic degeneration, which is inhibited by angiotensin
receptor blockers and angiotensin converting enzyme (ACE) inhibitors. Several factors
may induce an increase in RAS activity in the dopaminergic system. A decrease in
dopaminergic activity induces compensatory upregulation of local RAS function in both
dopaminergic neurons and glia. In addition to its role as an essential neurotransmitter,
dopamine may also modulate microglial inflammatory responses and neuronal OS via
RAS. Important counterregulatory interactions between angiotensin and dopamine have
also been observed in several peripheral tissues. Neurotoxins and proinflammatory factors
may also act on astrocytes to induce an increase in RAS activity, either independently of
or before the loss of dopamine. Consistent with a major role of RAS in dopaminergic
vulnerability, increased RAS activity has been observed in the nigra of animal models
of aging, menopause and chronic cerebral hypoperfusion, which also showed higher
dopaminergic vulnerability. Manipulation of the brain RAS may constitute an effective
neuroprotective strategy against dopaminergic vulnerability and progression of Parkinson’s
disease.
Keywords: aging, angiotensin, dopamine, NADPH-oxidase, neurodegeneration, neuroinflammation, oxidative
stress, parkinson
INTRODUCTION
The renin-angiotensin system (RAS) was initially considered as a
circulating humoral system, with functions in regulating blood
pressure and in sodium and water homeostasis. The RAS is
phylogenetically one of the oldest hormone systems. It has been
suggested that the RAS played an important role in human
evolution, and it is possible that our ancestors may have survived
on little salt, thanks to RAS activation (Lev-Ran and Porta,
2005). Angiotensin II (AII), which is the most important effector
peptide of the RAS, is formed by the sequential action of two
enzymes -renin and angiotensin converting enzyme (ACE)- on
the precursor glycoprotein angiotensinogen. The actions of AII
are mediated by two main cell receptors: AII type 1 and 2 (AT1
and AT2) receptors (Unger et al., 1996; Oro et al., 2007; Jones
et al., 2008). In addition to the afore mentioned components of
the RAS, several other components that are involved in secondary
mechanisms of this system have emerged (Cuadra et al., 2010;
Wright and Harding, 2013). The AT1 receptor mediates most of
the classical peripheral actions of AII. It is generally considered
that AT2 receptors exert actions directly opposed to those medi-
ated by AT1 receptors thus antagonizing many of the effects of the
latter (Chabrashvili et al., 2003; Jones et al., 2008). However, the
relationships between AT1 and AT2 are probably more complex
and remain to be fully clarified.
THE LOCAL (TISSUE OR PARACRINE) RAS. ROLE IN
OXIDATIVE STRESS, INFLAMMATION AND TISSUE
DEGENERATION
It is now known that, in addition to the “classical” humoral RAS,
many tissues have local (tissue or paracrine) RAS that contain
the different components previously described for the circulat-
ing RAS (Ganong, 1994; Re, 2004). Although both circulating
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RAS and local RAS act together in different tissues, it is gen-
erally accepted that circulating components are far less impor-
tant than local formation of angiotensins for functioning of the
system. Abnormal upregulation of local AII induces oxidative
stress (OS) damage and exacerbates of inflammation. AII is a
major activator of the NADPH-oxidase complex (Zalba et al.,
2001; Touyz, 2004; Hoogwerf, 2010) which is the most important
intracellular source of reactive oxygen species (ROS) other than
mitochondria (Babior, 1999, 2004; Cai, 2005). It is known that
NADPH-dependent oxidases are upregulated in major aging-
related diseases such as hypertension, diabetes and atherosclerosis
(Griendling et al., 2000; Münzel and Keany, 2001). It is usually
considered that activation of AT2 receptors inhibits NADPH-
oxidase activation and counteracts the deleterious effects of
AT1 activation. In peripheral tissues, the upregulated AII acts,
via AT1 receptors, on the resident cells (i.e., endothelial cells,
smooth muscle cells) leading to OS, and subsequent production
of chemokines, cytokines, and adhesion molecules, which con-
tribute to the migration of inflammatory cells into the injured
tissue (Ruiz-Ortega et al., 2001; Suzuki et al., 2003). Furthermore,
AII acts on inflammatory cells to induce inflammatory responses
and to release high levels of ROS mainly by activation of the
NADPH complex (Okamura et al., 1999; Yanagitani et al., 1999;
Qin et al., 2004; Touyz, 2004).
Finally, in addition to the “classical” humoral RAS and the
local or tissue RAS, a number of recent studies support the
existence of third level of RAS in several types of cells (Baker
et al., 2004): the intracellular or intracrine RAS. The existence
of functional intracellular RAS opens up new perspectives for
understanding the effects of the RAS and for the management of
RAS-related diseases (Kumar et al., 2007, 2009).
THE BRAIN RAS. LOCAL RAS IN THE NIGROSTRIATAL
DOPAMINERGIC SYSTEM
The role of the RAS on brain function was initially associated with
effects of the circulating RAS in areas involved in the central con-
trol of blood pressure and sodium and water homeostasis, which
are located in circumventricular organs lacking the blood-brain
barrier (von Bohlen und Halbach and Albrecht, 2006; Phillips
and de Oliveira, 2008). However, over the last two decades, all
components of the classical RAS have been identified in different
brain areas inside the blood-brain barrier, and the brain RAS
has been suggested to be involved in additional functions and
disorders (Kerr et al., 2005; Maul et al., 2005; Saavedra, 2005;
Saab et al., 2007). Interestingly, it has been observed that brain
levels of AII are much higher than circulating levels (Hermann
et al., 1984), and that the precursor protein angiotensinogen is
mainly produced by astrocytes (Stornetta et al., 1988; Milsted
et al., 1990), although it is also produced at low levels in neurons
(Kumar et al., 1988; Thomas et al., 1992). Major components
involved in the effects of AII in peripheral tissues such as NADPH-
oxidases have also been located in neurons (Noh and Koh, 2000;
Wang et al., 2004) and glial cells (Gao et al., 2003; Wu et al.,
2003). Several studies have shown that, as previously observed
in peripheral organs, AT1 receptor blockers and ACE inhibitors
(ACEIs) decreased the inflammatory response in the CNS (Platten
et al., 2009; Stegbauer et al., 2009; Saavedra, 2012). In accordance
with their inhibitory effect on brain inflammation, beneficial
effects of AT1 inhibition have been observed in a number of
processes mediated by microglial activation and neuroinflamma-
tion, including animal models of Alzheimer’s disease (Kehoe and
Wilcock, 2007; Mogi and Horiuchi, 2009), brain ischemia (Lou
et al., 2004; Iwanami et al., 2010) and multiple sclerosis (Platten
et al., 2009; Stegbauer et al., 2009).
Several studies have reported the presence of RAS compo-
nents in the basal ganglia, particularly in the nigrostriatal system
(Quinlan and Phillips, 1981; Simonnet et al., 1981; Brownfield
et al., 1982; Chai et al., 1987; Allen et al., 1992). In recent studies
(Rodriguez-Pallares et al., 2008; Joglar et al., 2009; Valenzuela
et al., 2010; Garrido-Gil et al., 2013b), we used laser confocal
microscopy and other methods to demonstrate the presence of
AT1 and AT2 receptors in nigral dopaminergic neurons and glial
cells (i.e., astrocytes and microglia) in rodents and primates,
including humans (Garrido-Gil et al., 2013b), as well as in pri-
mary mesencephalic cell cultures (Rodriguez-Pallares et al., 2004,
2008; Joglar et al., 2009). Furthermore, we demonstrated the
presence of different cytoplasmatic and membrane subunits of
the NADPH complex in mesencephalic dopaminergic neurons,
astrocytes and microglia (Rodriguez-Pallares et al., 2007, 2008;
Joglar et al., 2009). Recently, we have described, for the first time,
prorenin receptors in nigral dopaminergic neurons and microglial
cells in humans, monkeys and rats (Valenzuela et al., 2010;
Garrido-Gil et al., 2013b). Interestingly, the labeling for prorenin,
AT1 and AT2 receptors was not only located at the cell surface
but also intracellularly in dopaminergic neurons and glial cells
(Garrido-Gil et al., 2013b). Therefore, our observations support
the existence of an intracellular/intracrine RAS in neurons, and
particularly in dopaminergic neurons, as previously suggested for
other cell types (Baker et al., 2004; Kumar et al., 2007, 2009).
INCREASED LOCAL RAS ACTIVITY ENHANCES
DOPAMINERGIC CELL VULNERABILITY: MECHANISMS
INVOLVED
In several recent studies, we used 6-OHDA and MPTP models
of parkinsonism to study the possible role of the brain RAS in
dopaminergic degeneration: the results suggest that enhanced
levels of AII, via AT1 receptors, exacerbate dopaminergic cell
death and may play a synergistic role in the pathogenesis and
progression of PD. Recent experimental data from other labora-
tories also support the involvement of brain RAS in dopaminergic
degeneration (Grammatopoulos et al., 2007; Zawada et al., 2011;
Sonsalla et al., 2013). It was observed that AII increased the neu-
rotoxic effect induced by low doses of dopaminergic neurotoxins,
and that treatment with ACEIs (Lopez-Real et al., 2005; Muñoz
et al., 2006; Sonsalla et al., 2013) or blockage of AT1 receptors
(Rey et al., 2007; Rodriguez-Pallares et al., 2008; Joglar et al., 2009)
led to significant reduction in the loss of dopaminergic neurons
and levels of protein oxidation and lipid peroxidation induced by
the neurotoxins (Sanchez-Iglesias et al., 2007). Interestingly, the
neuronal loss was also reduced by inhibitors of NADPH-oxidase
activation, which suggests that NADPH activation and NADPH-
derived ROS are involved in the AII-enhanced dopaminergic
neuron death (Rey et al., 2007; Rodriguez-Pallares et al., 2008;
Joglar et al., 2009).
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In peripheral tissues (see above) and brain (Benicky et al.,
2009; Wright and Harding, 2013), abnormal upregulation of local
AII induces OS damage and exacerbates inflammation. Oxidative
stress and neuroinflammation (including microglial NADPH-
oxidase activation) constitute early components of dopaminergic
cell death and both factors act synergistically with others to induce
progression of PD (Gao et al., 2003; Wu et al., 2003; Rodriguez-
Pallares et al., 2007). In the substantia nigra, AII receptors and
NADPH-oxidase were observed in dopaminergic neurons and
glial cells. Therefore, AII may also enhance dopaminergic degen-
eration through several mechanisms, as previously observed in
the vessel wall (Figure 1). First, AII acts on neurons (i.e., resident
cells) via AT1 receptors and stimulates production of low levels
of intraneuronal ROS by activation of neuronal NADPH-oxidase.
ROS act as second messengers in several signaling pathways,
including those involved in triggering the inflammatory response
and the migration of inflammatory cells into the lesioned area;
NADPH-derived ROS also modulate neuronal levels of ROS by
interacting with mitochondria-derived ROS and with ROS from
other sources such as dopaminergic neurotoxins or activated
microglia. Feed-forward cross-talk signaling between NADPH
oxidase-derived ROS and mitochondria-derived ROS has been
observed in several types of cells (Doughan et al., 2008; Wosniak
et al., 2009). This interaction has recently been confirmed in a
dopaminergic cell line treated with the neurotoxin MPP+ and
angiotensin (Zawada et al., 2011) and in our recent studies with
primary cultures of dopaminergic cells (Rodriguez-Pallares et al.,
2009, 2012). Second, AII acts on microglia (i.e., inflammatory
cells), in which NADPH oxidase activation produces high con-
centrations of ROS, which are released extracellularly and affect
neurons; AII also produces low levels of microglial intracellular
ROS, which act as a second messenger in several microglial sig-
naling pathways involved in the inflammatory response (Babior,
2004; Qin et al., 2004). We have recently shown that activation of
the microglial RhoA/ROCK pathway (Villar-Cheda et al., 2012a;
Borrajo et al., 2014b), release of microglial TNF-α (Borrajo
et al., 2014a), and altered iron homeostasis (Garrido-Gil et al.,
2013a) are involved in the enhancing effect of AII/AT1 acti-
vation on the microglial response and dopaminergic degener-
ation. Activation of peroxisome proliferator-activated receptor
gamma (PPAR-γ) also mediates the neuroprotective and anti-
inflammatory effects of AT1 receptor inhibition (Garrido-Gil
et al., 2012).
FACTORS THAT MAY INCREASE RAS ACTIVITY IN THE
NIGROSTRIATAL DOPAMINERGIC SYSTEM
Interaction between dopamine and angiotensin was initially sug-
gested to occur in the basal ganglia because acute administration
of AII directly into the striatum (via microdialysis probes)
induced an increase in extracellular levels of dopamine in normal
rats, which was blocked by co-administration of AT1 receptor
antagonists (Mendelsohn et al., 1993; Brown et al., 1996). This
suggested that AII, via AT1 receptors, facilitates the release of
dopamine. However, acute or chronic administration of AT1
receptor antagonists alone did not alter striatal dopamine levels
(Dwoskin et al., 1992; Mendelsohn et al., 1993; Brown et al., 1996;
Jenkins, 2008). This was attributed to possible compensatory
mechanisms, which we have recently investigated in normal rats
and dopaminergic denervated rats (Dominguez-Meijide et al.,
2014). Therefore, it seems reasonable to assume that a decrease
in dopaminergic activity may induce a compensatory increase
in RAS activity to increase striatal dopamine. However, if the
dopaminergic system is impaired (e.g., in the initial stages of
dopaminergic lesions or aging), normal dopaminergic levels can-
not be reached and the resulting overactivation of the RAS may
exacerbate the microglial inflammatory response and produce
OS, leading to progression of dopaminergic vulnerability and
neurodegeneration. In a series of recent studies, we have con-
firmed that a decrease in dopaminergic activity induces compen-
satory upregulation of local RAS function in both dopaminergic
neurons and glia (Figure 1). It is known that both angiotensin
(Rodriguez-Pallares et al., 2004, 2008; Joglar et al., 2009; Garrido-
Gil et al., 2013b) and dopamine (Miyazaki et al., 2004; Färber
et al., 2005) receptors are located in neurons, microglia and
astrocytes. In the nigrostriatal system, we observed that dopamine
depletion induced a significant increase in AT1 and AT2 recep-
tor expression, and NADPH-oxidase complex activity, which
decreased as dopamine function was restored (Villar-Cheda et al.,
2010). More recently, we investigated the possible interactions
between angiotensin and dopamine receptors in D1-, D2-, and
AT1-deficient mice, as well as mice over-expressing D2 recep-
tors. A counter-regulatory mechanism between dopamine and
angiotensin receptors was observed in the striatum and substantia
nigra of these mice (Villar-Cheda et al., 2014). A similar inter-
action between dopamine and angiotensin receptors has recently
been demonstrated in peripheral tissues, particularly in relation
to the regulation of renal sodium excretion and cardiovascular
function (Zeng et al., 2006; Khan et al., 2008; Gildea, 2009; Padia
et al., 2012).
Other factors may induce an increase in RAS activity inde-
pendently or before the loss of dopamine (Figure 1). It is known
that dopaminergic neurotoxins such as MPP+ can act directly on
astrocytes to induce an increase in production of proinflamma-
tory factors (Henze et al., 2005; Block et al., 2007); astrocytes are
the main source of angiotensinogen/angiotensin (Stornetta et al.,
1988; Milsted et al., 1990), which may then act on neurons and
microglial cells as indicated above. A loss of estrogen and other
mechanisms that inhibit the neuroinflammatory response may
also induce RAS activation and lead to an increase in dopamin-
ergic neuron vulnerability as detailed below.
DOPAMINERGIC VULNERABILITY IN AGING, MENOPAUSE
AND BRAIN HYPOPERFUSION. ROLE OF RAS HYPERACTIVITY
In recent studies, we investigated whether enhanced RAS activity
in the nigra may be involved in the increased vulnerability of
dopaminergic neurons to degeneration observed in aging, post-
menopause or chronic cerebral hypoperfusion. Several studies
have shown that normal aging is associated with a proinflam-
matory and pro-oxidant state that may favor an exaggerated
response to injury and degenerative diseases (Csiszar et al., 2003;
Ungvari et al., 2004; Choi et al., 2010). We have confirmed that, in
aged male rats, aging enhances levels of neuroinflammation, OS
markers and dopaminergic cell death induced by dopaminergic
neurotoxins. The nigral RAS is involved in these effects, and levels
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FIGURE 1 | Model of the role that brain RAS plays in dopaminergic cell
vulnerability. Different pathogenic factors (e.g., mitochondrial dysfunction,
aging-related changes, neurotoxins, etc.) may initiate dopaminergic lesions
and diminish dopaminergic function, which leads to increased RAS activation
and progression of the dopaminergic degeneration. Furthermore, neurotoxins
and proinflammatory factors may act directly on astrocytes and induce an
increase in ANG/AII production, which leads to an increase in RAS activity and
dopaminergic vulnerability. In dopaminergic neurons, increased RAS activity
(via AT1 receptors) increases NADPH-oxidase activity, which enhances
intraneuronal ROS production (in an interaction with mitochondria) and
pro-inflammatory signals. In microglial cells, increased RAS activity stimulates
the NADPH-oxidase complex, which enhances the inflammatory response,
promoting extracellular release of high levels of ROS, activation of ROCK, and
the release of cytokines and different neurotoxic factors. ANG,
angiotensinogen; AII, angiotensin II; AT1, angiotensin type I receptors; DA,
dopamine; E2, estrogen; NADPH, NADPH-oxidase complex; RAS,
renin-angiotensin system; ROCK, Rho-associated kinase; ROS, reactive
oxygen species.
of neuroinflammation, OS markers and dopaminergic cell death
are reduced by treatment with the AT1 antagonist candesartan
(Villar-Cheda et al., 2012b, 2014). Numerous studies in animal
models and humans have shown aging-related loss of striatal
D2 and D1 receptors (Wang et al., 1998; Ishibashi et al., 2009;
Rieckmann et al., 2011), and that the dopaminergic system is
altered during normal aging (Kubis et al., 2000; Collier et al.,
2007). Therefore, the RAS upregulation that we observed in aged
rats may be part of the compensatory changes related to decreased
levels of dopamine or dopamine receptors (Villar-Cheda et al.,
2012b, 2014). However, other factors may also be involved (Cruz-
Muros et al., 2007, 2009), as aging has been shown to be associated
with overactivation of RAS in a number of tissues (Thompson
et al., 2000; Min et al., 2009; Cassis et al., 2010). Thus, the
upregulation of AT1 receptors observed in aged rats may be part of
the compensatory changes related to changes in the dopaminergic
system; however, the compensatory upregulation of AT2 receptors
observed in young rats with similar changes in the dopaminergic
system was not observed in aged rats.
Menopause has also been identified as a prominent risk factor
for PD. Numerous experimental studies have shown that estrogen
exerts protective effects against dopaminergic cell degeneration
(Leranth et al., 2000; Callier et al., 2002). The anti-inflammatory
effects of estrogen play a major role in the neuroprotective effects
(Suzuki et al., 2007; Vegeto et al., 2008), although direct anti-
apoptotic (Das et al., 2011; Brendel et al., 2013) and trophic
(López-Martín et al., 1999; Campos et al., 2012) effects on
neurons have also been suggested. A number of epidemiolog-
ical studies have also reported that the incidence and preva-
lence of PD is higher in postmenopausal women and men than
in premenopausal women of similar age (Currie et al., 2004;
Ragonese et al., 2006a,b). However, some reported effects of
estrogen replacement therapy are controversial (Shulman, 2002;
Popat et al., 2005), and the age and duration of lack of estrogen
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in women receiving the treatment appear to be major factors in
the discrepancies. Interestingly, estrogen-induced regulation of
the RAS mediates beneficial effects of estrogen in several tissues
(Nickenig et al., 1998; Dean et al., 2005; Chen et al., 2008),
and interactions between estrogen and AII receptors have also
been observed (Liu et al., 2002; Tsuda et al., 2005; Xue et al.,
2007; Hoshi-Fukushima et al., 2008). In several recent studies
we have observed that the lack of estrogen increases RAS activity
in the substantia nigra in females (Rodriguez-Perez et al., 2010,
2011, 2012). We compared young ovariectomized rats (i.e., early
surgical menopause) with aged rats (i.e., natural menopause).
Both groups of menopausal rats showed increased RAS activ-
ity. However, estrogen therapy significantly reduced 6-OHDA-
induced dopaminergic cell loss in young rats but not in aged rats,
suggesting that other factors are involved in aged females. Interest-
ingly, treatment with the AT1 antagonist candesartan significantly
reduced dopaminergic neuron loss in both groups of menopausal
rats (Rodriguez-Perez et al., 2012).
Dopaminergic cell loss and signs parkinsonism have been
observed in elderly people without PD (almost 40%; Buchman
et al., 2012), and presynaptic dopaminergic function is reduced in
most patients with vascular parkinsonism (Zijlmans et al., 2007),
suggesting an interaction between aging-related cerebrovascu-
lar disease/brain hypoperfusion and dopaminergic degeneration.
This was confirmed in a recent study with animal models of
chronic brain hypoperfusion (Rodriguez-Perez et al., 2013), in
which we have shown that chronic hypoperfusion increases
dopaminergic cell death by enhancing the deleterious effects of
other factors (such as low doses of dopaminergic neurotoxins).
This suggests that hypoperfusion derived from aging and/or vas-
cular disease may increase the risk of development of parkin-
sonism. The mechanistic links between hypoperfusion/vascular
disease and neurodegeneration are unknown. However, chronic
hypoperfusion led to increased expression of inflammatory mark-
ers such as IL-1β and increased levels of OS markers such
as NADPH activity (Rodriguez-Perez et al., 2013), which have
been shown to be involved in the progression of dopaminergic
cell death in animal models of PD and in PD patients (Wu
et al., 2003; Koprich et al., 2008). Interestingly, these changes
were accompanied by increased RAS activity in the substantia
nigra, and they were inhibited by chronic treatment with the
AT1 receptor antagonist candesartan (Rodriguez-Perez et al.,
2013).
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